Patent application number | Description | Published |
20110003837 | MODIFIED RELEASE FORMULATIONS OF HMG COA REDUCTASE INHIBITORS - Modified release formulations of HMG Co-A reductase inhibitors, which provide reduced incidence of rhabdomyolysis, renal toxicity and other side effects by increasing hepatic bioavailability and decreasing systemic availability upon oral administration. The modified release pharmaceutical formulation comprises a therapeutically effective amount of HMG CoA reductase inhibitor or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), prodrug or metabolite thereof, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein the modified release formulation provides reduced incidence of adverse effects and improved efficacy when compared to the immediate release formulation upon oral administration. | 01-06-2011 |
20120027855 | PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY - The present invention relates to controlled release pharmaceutical formulations of active principle(s) like tetracycline-class antibiotics for providing increased residence time in the gastrointestinal tract and the process of preparing them. | 02-02-2012 |
20120283252 | PROCESS FOR PREPARING PHARMACEUTICAL OPHTHALMIC COMPOSITIONS - Pharmaceutical ophthalmic compositions comprising active ingredient(s) such as carbonic anhydrase inhibitor (CAI) or combinations and processes for making such compositions and the use of these compositions in patient populations including pediatric populations. A process for preparing an ophthalmic composition comprising a carbonic anhydrase inhibitor, which comprises a) preparing a slurry comprising a carbonic anhydrase inhibitor and a surfactant; b) preparing a polymer slurry comprising a polymer and water; c) preparing a solution comprising tonicity and preservative agents; d) mixing the polymer slurry of step b and the solution of step c, to form a vehicle concentrate and adjusting pH; e) adding the slurry of step a, to the vehicle concentrate of step d and mixing to homogenize; f) autoclaving the mixture of step e; g) sizing the mixture of step f, under aseptic condition. | 11-08-2012 |
20130004545 | SLOW RELEASE PHARMACEUTICAL COMPOSITIONS OF ILOPERIDONE - A slow release pharmaceutical composition comprising iloperidone or its active metabolites and a slow release agent is described. Also disclosed is slow release pharmaceutical composition comprising iloperidone or its active metabolites, wherein the slow release composition is a combination of a controlled release composition and an immediate release composition. | 01-03-2013 |
20130022654 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF TAPENTADOL - A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean T | 01-24-2013 |
20130142849 | CONTROLLED RELEASE FORMULATIONS OF DRONEDARONE - The present invention relates to controlled release formulation of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of controlled release formulations of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day. | 06-06-2013 |
20130143897 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BLONANSERIN - An oral controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) and optionally pharmaceutically acceptable excipients is provided. The present invention further relates to a controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) such that the composition releases not less than about 80% of Blonanserin within 20 hours, when dissolution is carried out in 900 ml, 0.1 N HCl, USP apparatus Type II (Paddle) at 50 rpm for 20 hrs. The controlled release pharmaceutical composition of the invention releases 50% of Blonanserin between about 4 to 14 hours, when dissolution is carried out in 900 ml, 0.1 N HCl, USP apparatus Type II (Paddle) at 50 rpm. | 06-06-2013 |
20130317063 | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BEPOTASTINE - The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria. | 11-28-2013 |
20130323309 | Sustained Release Composition of Memantine - A sustained release pharmaceutical composition comprising; a core including memantine or its pharmaceutically acceptable salts and one or more pharmaceutical acceptable excipients, and a sustained release coating comprising a water insoluble substance and a water soluble substance where the ratio of the water insoluble substance to the water soluble substance is from about 1:0 to about 3:5:1, optionally containing an immediate release coating having memantine where the immediate release coating is applied over the sustained release coating. | 12-05-2013 |
20140274970 | Controlled Release Pharmaceutical Dosage Forms - The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions. | 09-18-2014 |
20150017242 | Bilayer Tablet of Dronedarone - The present invention relates to multi component composition of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of multi component composition of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day. | 01-15-2015 |
20150150809 | Immediate Release Compositions and Methods For Delivering Drug Formulations Using Weak Acid Ion Exchange Resins In Abnormally High pH Environments - Multi-layer solid oral dosage immediate release and extended release compositions and methods for delivering drugs in abnormally high pH environments wherein the extended release layer is formed from a drug resinate of a strong acid ion-exchange resin and a release rate retarding polymer compressed together. | 06-04-2015 |
Patent application number | Description | Published |
20130225600 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS - The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I). | 08-29-2013 |
20150111900 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS - The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel. | 04-23-2015 |
20150111925 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS - The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel. | 04-23-2015 |
20160022673 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS - The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I). | 01-28-2016 |
Patent application number | Description | Published |
20110092847 | MRI Biopsy Targeting Cube with Snap Corners - A biopsy system comprises a control module, a localization assembly, a biopsy device, and a targeting cube. The biopsy device and/or other associated components are configured to selectively couple with a targeting cube that selectively couples with a grid plate having apertures for receiving the cube. The targeting cube comprises a body defined by faces. The targeting cube further comprises guide holes that originate and terminate at the faces and pass through the body of the targeting cube to provide passageways through the cube. To securely and removably fit the targeting cube within a grid plate aperture, the targeting cube also comprises deflectable projections positioned at the corners of the cube or extending from the faces of the cube. The projections are resiliently biased to extend outwardly, and are inwardly deflectable by the walls of a grid plate aperture to secure the targeting cube in position within the aperture. | 04-21-2011 |
20110092848 | MRI Biopsy Targeting Cube with Eccentric Lock - A biopsy system comprises a control module, a localization assembly, a biopsy device, and a targeting cube. A probe and/or other associated components of the biopsy device are configured to selectively couple with the targeting cube, which is configured to selectively couple with a grid plate. The targeting cube may comprise an eccentric lock for securing the targeting cube within the grid plate. The targeting cube may further comprise an elastomeric insert positioned within guide holes of the targeting cube for securing the probe and/or other associated components within the guide hole of the targeting cube. The guide holes of the targeting cube may alternatively, or in addition, include an elastomeric retaining ring within the passageway of the guide hole. | 04-21-2011 |
20110092849 | MRI Biopsy Targeting Cube with Gripping Arms - A biopsy system comprises a control module, a localization assembly, a biopsy device, and a targeting cube. The biopsy device and/or other associated components are configured to selectively couple with a targeting cube that selectively couples with a grid plate having apertures for receiving the targeting cube. The targeting cube comprises a body defined by faces. The targeting cube further comprises guide holes that originate and terminate at the faces and pass through the body of the targeting cube to provide passageways through the targeting cube. To securely and removably fit the targeting cube within a grid plate aperture, the targeting cube also comprises a pair of gripping arms. The gripping arms extend from two opposing faces of the cube and snap fit around the walls of the grid plate to secure the targeting cube in position. The arms are resiliently biased to engage the grid plate. | 04-21-2011 |
20110092850 | MRI Biopsy Targeting Guide with Rotational Lock - A biopsy system comprises a control module, a localization assembly, a biopsy device, and a targeting device. A probe and/or other associated components of the biopsy device are configured to selectively couple with the targeting device, which is configured to selectively couple with a grid plate. The targeting device may comprise a rotational lock for securing the targeting device within the grid plate. The targeting device may further comprise an elastomeric insert positioned within guide holes of the targeting device for securing the probe and/or other associated components within the guide hole of the targeting device. The guide holes of the targeting device may alternatively, or in addition, further comprise one or more retaining rings positioned within guide holes of the targeting device for securing the probe and/or other associated components within the guide hole of the targeting device. | 04-21-2011 |
20110092983 | MRI Biopsy Targeting Cube with Locking Flap - A biopsy system comprises a control module, a localization assembly, a biopsy device, and a targeting cube. A probe and/or other associated components of the biopsy device are configured to selectively couple with the targeting cube, which is configured to selectively couple with a grid plate. The targeting cube may comprise a locking flap for securing the targeting cube within the grid plate and/or for securing the probe and/or other associated components within the guide hole of the targeting cube. The locking flap may be operatively configured to deflect and/or compress thereby providing assistance in securing the targeting cube within the grid plate and/or securing the probe and/or other associated components within the guide hole of the targeting cube. | 04-21-2011 |